Abbott Laboratories (NYSE: ABT) says it has entered into a licensing agreement to commercialize products of India's Zydus Cadila in 15 emerging markets in a bid to accelerate Abbott's growth in those areas; the company also set up a business unit to concentrate on the developing world. Release | Report